

十字花科黑腐菌之熱穩定苯丙胺酸氫化? : 基因選殖與酵素活性分析

余明恩、簡宏堅

E-mail: 9701201@mail.dyu.edu.tw

摘要

現今醫學對於帕金森氏症 (Parkinson ' s disease) 的治療使用化學合成的 L-dopa 當做治療藥物，在經過一段時間的治療，會產生許多的副作用，而科學界對於帕金森氏症的研究著重於基因療法 (Gene Therapy) 和幹細胞的研究，希望能夠重建腦內 Aromatic amino acid decarboxylase (AADC) 酵素的量或是重建腦內黑質區 (substantia nigra) 的細胞，但是都仍屬於動物實驗的階段，所以在此過渡期，天然合成的 L-dopa 變為一個可以替代的方向。L-dopa 是由 phenylalanine 被 苯丙胺酸氫化? (phenylalanine hydroxylase) 轉換成 tyrosine，再被酪胺酸氫化? (tyrosine hydroxylase) 轉換成 L-dopa。本實驗針對來自十字花科黑腐菌 (*Xanthomonas campestris* pv. *campestris* 17) 的 phenylalanine hydroxylase 作一系列的研究，研究它的最適反應條件以及是否帶有 tyrosine hydroxylase 的活性，研究結果發現此蛋白質的 ORF (open reading frame) 全長 891 bp，轉譯成蛋白質一共是由 296 個胺基酸所組成，蛋白質分子量大小約為 33 kDa，為一胞內酵素，最適反應 pH 為 6.8，最適反應溫度為 50，並且是一個需要二價鐵離子的酵素，對於其他金屬離子沒有依賴，此酵素並不帶有 tyrosine hydroxylase 及 tryptophan hydroxylase 的活性。

關鍵詞：帕金森氏症

目錄

1. 前言.....	1 1.1 胺基酸.....	1 1.2 芳香族胺基酸.....	2 1.3 Phenylalanine 的代謝.....	2 1.4 苯丙胺酸氫化? (Phenylalanine hydroxylase). 3 1.5 苯丙酮尿症 (Phenylketonuria, PKU).....	5 1.6 酪胺酸氫化? (tyrosine hydroxylase).....	6 1.7 帕金森氏症 (Parkinson ' s disease).....	6 2. 研究動機.....	8 3. 材料與方法.....	9 3.1 實驗用品.....	9 3.11 菌種及質體.....	9 3.12 實驗藥品.....	9 3.13 培養液.....	9 3.14 製備 DNA 電泳膠片.....	10 3.15 製備蛋白質電泳膠片 (SDS-Polyacrylamide Gel).....	10 3.16 實驗試劑組.....	11 3.17 酵素.....	12 3.18 引子 (primer).....	12 3.19 分析軟體.....	12 3.2 實驗方法.....	13 3.2.1 DNA 之回收.....	13 3.2.2 抽取 E. coli 質體 (plasmid) DNA (傳統法).....	13 3.2.3 萃取染色體 DNA.....	14 3.2.4 聚合? 嘔礫狹 (Polymerase Chain Reaction).....	15 3.2.5 表現載體 pQE30 之構築.....	16 3.2.6 製備大腸桿菌 (E. coli) 勝任細胞 (competent cell).....	17 3.2.7 大腸桿菌的轉形作用 (transformation).....	17 3.2.8 苯丙胺酸氫化? j 量表現與蛋白回收.....	18 3.2.9 苯丙胺酸氫化? 拈 A pH 值測定.....	19 3.2.10 苯丙胺酸氫化? 拈 A 溫度測定.....	20 3.2.11 苯丙胺酸氫化? 獄簿嶼 坩觸 v.....	21 3.2.12 金屬離子對於苯丙胺酸氫化? 獐 v 響.....	21 3.2.13 苯丙胺酸氫化? 漕? 閩礫狹 w.....	22 3.2.14 苯丙胺酸氫化? 熔厶咩礫狹 w.....	23 3.2.15 苯丙胺酸氫化? 鵠顛峻踟礫 i 基酸的專一性測定.....	24 4. 結果.....	25 4.1 萃取 <i>Xanthomonas campestris</i> 的染色體 DNA.....	25 4.2 苯丙胺酸氫化? 債狐 (reading frame) 基因分析.....	25 4.3 苯丙胺酸氫化? 熙 J 白質表現與分析.....	25 4.4 苯丙胺酸氫化? 拈 A pH 值.....	26 4.5 苯丙胺酸氫化? 拈 A 溫度.....	27 4.6 苯丙胺酸氫化? 鵠顛峻踟礫 i 基酸的專一性.....	27 4.7 受質濃度對於苯丙胺酸氫化? 獐 v 響.....	27 4.8 苯丙胺酸氫化? 漕? 閩礫狹 帶厶咩礫?.....	28 4.9 金屬離子對於苯丙胺酸氫化? 獐 v 響.....	28 5. 討論.....	29 5.1 苯丙胺酸氫化? 熙 J 白質表現與回收.....	29 5.2 受質濃度對於苯丙胺酸氫化? 獐 v 響.....	29 5.3 苯丙胺酸氫化? 快峇狹陰嚙?.....	29 5.4 苯丙胺酸氫化? 債狐 (reading frame) 與各種生物的比較.....	30 5.5 過高受質濃度對於苯丙胺酸氫化? 獐 v 響.....	31 5.6 過高產物濃度對於苯丙胺酸氫化? 獐 v 響.....	31 5.7 苯丙胺酸氫化? 滷 M 一性.....	32 6. 結論.....	33 參考文獻.....	58 附錄.....	62
------------	----------------	-------------------	------------------------------	--	--	--	----------------	-----------------	-----------------	-------------------	------------------	-----------------	-------------------------	---	--------------------	-----------------	--------------------------	-------------------	------------------	-----------------------	---	-------------------------	---	------------------------------	--	--	----------------------------------	----------------------------------	---------------------------------	---------------------------------	------------------------------------	---------------------------------	--------------------------------	---	---------------	---	---	---------------------------------	------------------------------	----------------------------	------------------------------------	---------------------------------	----------------------------------	---------------------------------	---------------	---------------------------------	---------------------------------	----------------------------	---	-----------------------------------	-----------------------------------	----------------------------	---------------	--------------	------------	----

參考文獻

1. Abita JP, Blandin-Savoja F, Rey F. 1987. Phenylalanine 4-monooxygenase from human liver. *Methods Enzymol.* 142:27-35.
2. Arias-Barrau E, Olivera ER, Luengo JM, Fernandez C, Galan B, Garcia JL, Diaz E, Minambres B. 2004. The homogentisate pathway: a central catabolic pathway involved in the degradation of L-phenylalanine, L-tyrosine, and 3-hydroxyphenylacetate in *Pseudomonas putida*. *J. Bacteriol.* 186 (15):5062-5077.
3. Belen PD, Vilaseca MA, Mas A, Lambruschini N, Artuch R, Gomez L, Pineda J, Gutierrez A, Mila M, Campistol J. 2004. Tetrahydrobiopterin responsiveness in patients with phenylketonuria. *Clinical Biochemistry* 37(12):1083-1090.
4. Celesia GG, Wanamaker WM. 1976.

L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease. *Dis Nerv Syst.* 37(3):123-5. 5. Chen. DW, Frey PA. 1998. Phenylalanine hydroxylase from *Chromobacterium violaceum*. *J Biol Chem.* 273(40):25594-601. 6. Citron BA, Davis MD, Kaufman S. 1992. Purification and biochemical characterization of recombinant rat liver phenylalanine hydroxylase produced in *Escherichia coli*. *Protein Expr Purif.* 3(2):93-100 7. Cotton RG, 1971. Phenylalanine hydroxylase of *Macaca irus*. Purification of two components of the enzyme. *Biochim Biophys Acta* 235(1):61-72. 8. Daubner SC, Melendez J, Fitzpatrick PF. 2000. Reversing the substrate specificities of phenylalanine and tyrosine hydroxylase: aspartate 425 of tyrosine hydroxylase is essential for L-DOPA formation. *Biochemistry* 39(32):9652-61. 9. Da Silva ACR, Ferro JA, Reinach FC, Kitajima JP. 2002. Comparison of the genomes of two *Xanthomonas* pathogens with different host specificities. *Nature* 417 (6887):459-463 10. Eisensmith RC, and Woo SL. 1992. Molecular basis of phenylketonuria and related hyperphenylalaninemia: mutations and polymorphisms in the human phenylalanine hydroxylase gene. *Hum. Mutat.* 1 (1), 13-23. 11. Fitzpatrick PF. 1991. Steady-state kinetic mechanism of rat tyrosine hydroxylase. *Biochemistry* 30(15):3658-62 12. Fitzpatrick PF. 2000. The aromatic amino acid hydroxylases. *Adv Enzymol Relat Areas Mol Biol* 74:235-94. 13. Fitzpatrick PF. 2003. Mechanism of aromatic amino acid hydroxylation. *Biochemistry* 42(48):14083-91. 14. Gibbs BS, Wojchowski D, Benkovic SJ. 1993. Expression of rat liver phenylalanine hydroxylase in insect cells and site-directed mutagenesis of putative non-heme iron-binding sites. *J Biol Chem.* 268(11):8046-52. 15. Hendriksz CJ, Walter JH. 2004. Update on phenylketonuria. *Current Paediatrics* 14(5):400-406. 16. Hufton SE, Jennings IG, Cotton RG. 1995. Structure and function of the aromatic amino acid hydroxylases. *Biochem J.* 311(2): 353-66. 17. Ledley FD, Grenett HE, Dunbar BS, Woo SL. 1990. Mouse phenylalanine hydroxylase: Homology and divergence from human phenylalanine hydroxylase. *Biochem J.* 267(2):399-405. 18. Leiros HK, Pey AL, Innselset M, Moe E, Leiros I, Steen IH, Martinez A. 2007. Structure of phenylalanine hydroxylase from *Colwellia psychrerythraea* 34H, a monomeric cold active enzyme with local flexibility around the active site and high overall stability. *J Biol Chem.* 282(30):21973-86. 19. Mannisto PT, Tuomainen P, Toivonen M, Tornwall M, Kaakkola S. 1990. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats. *J Neural Transm Park Dis Dement.* 2(1):31-43. 20. Morris ME, Iansek R. 1996. Characteristics of motor disturbance in Parkinson's disease and strategies for movement rehabilitation. *Human Movement Science.* 15(5):649-669. 21. Oh HJ, Lee H, Park JW, Rhee HS, Koo SK, Kang SM, Jo I, Jung SC. 2005. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy. *Mol Genet Metab.* 86(S1)24-32. 22. Onishi A, Liotta LJ, Benkovic SJ. 1991. Cloning and expression of *Chromobacterium violaceum* phenylalanine hydroxylase in *Escherichia coli* and comparison of amino acid sequence with mammalian aromatic amino acid hydroxylases. *J Biol Chem.* 266(28):18454-9. 23. Pember SO, Johnson KA, Villafraña JJ, Benkovic SJ. 1989. Mechanistic studies on phenylalanine hydroxylase from *Chromobacterium violaceum*. Evidence for the formation of an enzyme-oxygen complex. *Biochemistry* 28(5):2124-30. 24. Richardson SC, Fisher MJ. 1993. Characterization of phenylalanine hydroxylase from rat kidney. *Int J Biochem.* 25(4):581-8. 25. Simon-Chazottes D, Matsubara S, Miyauchi T, Muramatsu T, Guenet JL. 1992. Chromosomal localization of two cell surface-associated molecules of potential importance in development: midkine (Mdk) and basigin (Bsg). *Mamm. Genome* 2 (4), 269-271. 26. Smith CD, Shu S, Mungall CJ, Karpen GH. 2007. The release 5.1 annotation of *Drosophila melanogaster* heterochromatin. *Science* 316 (5831), 1586-1591. 27. Vieille C, Zeikus GJ. 2001. Hyperthermophilic enzymes: sources, uses, and molecular mechanisms for thermostability. *Microbiol Mol Biol Rev.* 65(1):1-43. 28. Woo SL, Gillam SS, Woolf LI. 1974. The isolation and properties of phenylalanine hydroxylase from human liver. *Biochem J.* 139(3):741-9. 29. Wretborn M, Humble E, Ragnarsson U, Engstrom L. 1980. Amino acid sequence at the phosphorylated site of rat liver phenylalanine hydroxylase and phosphorylation of a corresponding synthetic peptide. *Biochem. Biophys. Res. Commun.* 93 (2), 403-408. 30. Zhao G, Xia T, Song J, Jensen RA. 1994. *Pseudomonas aeruginosa* possesses homologues of mammalian phenylalanine hydroxylase and 4 alpha-carbinolamine dehydratase/DCoH as part of a three-component gene cluster. *Proc. Natl. Acad. Sci.* 91 (4):1366-1370. 31. Zoidakis J, Loaiza A, Vu K, Abu-Omar MM. 2005. Effect of temperature, pH, and metals on the stability and activity of phenylalanine hydroxylase from *Chromobacterium violaceum*. *J Inorg Biochem.* 99(3):771-5.